Evaro

| Aspect | Evaro (embedded prescription infrastructure) | ZAVA (online doctor + pharmacy) | Kry/Livi (virtual GP/telehealth) | |--------|---------------|----------------|----------------| | Starting Price | Not publicly listed (partner contracts; pricing disclosed through agreements) | Consumer pricing varies by treatment (publishes consumer "from" pricing) | Pricing varies (often employer/NHS/private arrangements; not consistently published) | | Best For | Consumer brands/apps seeking to embed regulated prescribing, dispensing, and delivery into their experiences | Consumers seeking direct-to-patient online prescriptions; also supports partner-branded services | Broader GP-like consult experience with synchronous video and continuity | | Key Strength | Integrated clinical, pharmacy, and fulfillment services with partner integration options | Established consumer-facing brand and published consumer pricing | Synchronous consult model and continuity of care for primary care needs | | Key Weakness | Limited public detail on enterprise security controls and some operational risks tied to fulfilment quality | Typically consumer-facing rather than an embedded infrastructure first | Less focused on e-commerce-style prescription fulfillment and brand-embedded experiences | - Direct competitors and their key differentiators - ZAVA - Public consumer pricing and large telemedicine footprint. - Has supported partner-branded services in some arrangements. - Numan / Manual - Verticalized DTC brands with subscription and community features; less positioned as B2B embedded infrastructure. - Kry/Livi - Focused on synchronous consultations and primary care continuity. - Feature comparison: where Evaro performs relatively strongly vs areas that are unclear - Areas of relative strength - Partner-focused embedding and the combination of consultation, prescribing, and fulfillment in a single vendor offering. - Vendor emphasis on regulatory licensing for pharmacy and clinical services. - Short, asynchronous questionnaire-based flows for straightforward prescribing scenarios (vendor-cited short questionnaire durations). - Areas of uncertainty or where Evaro lags public comparators - Public disclosure of enterprise-grade security and compliance controls. - Public developer documentation and API specifications. - Independent evidence of clinical outcomes beyond convenience and throughput metrics. - Pricing comparison: value proposition vs alternatives - Evaro - Likely contract-based, with revenue-share / per-transaction models; public information is insufficient to benchmark precisely. - ZAVA - Publishes consumer "from" pricing for many treatments, providing more transparent consumer-level comparisons. - Customer testimonials comparing Evaro to competitors - Community anecdotes compare packaging practices and pricing in specific medication categories; these are anecdotal and focused on specific treatments (e.g., GLP-1 therapies). - Market share and adoption trends - Publicly available data is insufficient to quantify market share for Evaro. - Funding and partner announcements suggest increased interest in embedded health infrastructure as a category, but boundaries and definitions of the category are still evolving.